BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,062,680 | +2.7% | 2,551,226 | +2.2% | 0.48% | +15.8% |
| Q2 2023 | $17,580,239 | -9.7% | 2,497,193 | +7.0% | 0.42% | -9.9% |
| Q1 2023 | $19,466,269 | -10.3% | 2,334,085 | +23.4% | 0.46% | -11.1% |
| Q4 2022 | $21,705,661 | +0.6% | 1,890,737 | +10.4% | 0.52% | -6.3% |
| Q3 2022 | $21,578,000 | +39.6% | 1,712,507 | +17.2% | 0.56% | +23.8% |
| Q2 2022 | $15,458,000 | +171.3% | 1,461,091 | +108.7% | 0.45% | +104.5% |
| Q1 2019 | $5,698,000 | +0.9% | 700,000 | 0.0% | 0.22% | -17.6% |
| Q4 2018 | $5,649,000 | +5.8% | 700,000 | 0.0% | 0.27% | +38.3% |
| Q3 2018 | $5,341,000 | +272.7% | 700,000 | +180.0% | 0.19% | +250.9% |
| Q2 2018 | $1,433,000 | -67.5% | 250,000 | -73.0% | 0.06% | -70.7% |
| Q1 2018 | $4,412,000 | +10.6% | 925,000 | +13.8% | 0.19% | +3.9% |
| Q4 2017 | $3,989,000 | +69.2% | 812,500 | +80.6% | 0.18% | +66.1% |
| Q3 2017 | $2,358,000 | – | 450,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |